絞り込み

17395

広告

日本人も「大きな一歩」を 月面着陸へ日米協力 (毎日新聞)

萩生田光一文部科学相と米航空宇宙局(NASA)のジム・ブライデンスタイン長官は10日、オンラインで会談し、米国の有人月面探査計画の日米協力に関する共同宣言に署名...

  1. 腸内ウイルス、治療に一役 酵素が腸炎菌を...
  2. ヒト受精卵使うゲノム編集了承 厚労省と文...
  3. コロナ後遺症、厚労省調査へ (毎日新聞)...
  4. 新型コロナ アビガン有効性結論出ず 藤田...

ニュース一覧

Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.

著者 Kustos SA , Fasinu PS
Medicines (Basel).2019 Oct 15 ; 6(4):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (40view , 0users)

Full Text Sources

Over the last ten years, a new class of drugs, known as the direct-acting oral anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the older generation anticoagulants, DOACs require specific reversal agents in cases of life-threatening bleeding or the need for high-risk surgery. Published literature was searched, and information extracted to provide an update on DOACS and their reversal agents. The DOACs include the direct thrombin inhibitor-dabigatran, and the factor Xa inhibitors-rivaroxaban, apixaban, edoxaban, and betrixaban. These DOACs all have a rapid onset of action and each has a predictable therapeutic response requiring no monitoring, unlike the older anticoagulants, such as warfarin. Two reversal agents have been approved within the last five years: idarucizumab for the reversal of dabigatran, and andexanet alfa for the reversal of rivaroxaban and apixaban. Additionally, ciraparantag, a potential "universal" reversal agent, is currently under clinical development. A new generation of anticoagulants, the DOACs, and their reversal agents, are gaining prominence in clinical practice, having demonstrated superior efficacy and safety profiles. They are poised to replace traditional anticoagulants including warfarin.
PMID: 31618893 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード